Publications by authors named "J Vojinovic"

Article Synopsis
  • The article discusses a long-term study on the safety and effectiveness of etanercept, a treatment for juvenile idiopathic arthritis (JIA), in children and young adults over a span of ten years.
  • JIA is an inflammatory condition that causes joint pain and stiffness, usually diagnosed before age 16, requiring ongoing treatment until the disease is in remission.
  • The research highlights the need to evaluate the long-lasting safety of etanercept, which modulates the immune system to alleviate symptoms of arthritis.
View Article and Find Full Text PDF

Objectives: The aim of the study was to establish an international multicenter registry to collect data on patients with Multisystem Inflammatory Syndrome in Children (MIS-C), in order to highlight a relationship between clinical presentation, age of onset and geographical distribution on the clinical outcome.

Study Design: Multicenter retrospective study involving different international societies for rare immunological disorders.1009 patients diagnosed with MIS-C between March and September 2022, from 48 centers and 22 countries were collected.

View Article and Find Full Text PDF

Objectives: To study circulating myeloperoxidase (MPO)-positive extracellular vesicles (MPOEVs) exposing citrullinated histone-3 (H3Cit), tissue factor (TF), and plasminogen (Plg) in association to thrombin generation in patients with anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV).

Methods: We have involved well-characterized patients with AAV together with population-based controls. Flow cytometry was used to assess the levels of MPOEVs in citrated plasma.

View Article and Find Full Text PDF

Objectives: CLIPPER2 was an 8-year, open-label extension of the phase 3b, 2-year CLIPPER study on the safety and efficacy of etanercept in patients with JIA, categorized as extended oligoarticular arthritis (eoJIA), enthesitis-related arthritis (ERA) or PsA.

Methods: Participants with eoJIA (2-17 years old), ERA or PsA (each 12-17 years old) who received ≥1 etanercept dose (0.8 mg/kg weekly; maximum 50 mg) in CLIPPER could enter CLIPPER2.

View Article and Find Full Text PDF